Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban.
Yu-Sheng LinFeng-Che KuanTze-Fan ChaoMichael WuShao-Wei ChenMien-Cheng ChenChang-Ming ChungPao-Hsien ChuGregory Y H LipVictor Chien-Chia WuPublished in: Cancer medicine (2021)
Compared with rivaroxaban, the use of dabigatran may be associated with a lower risk of cancer-related death and all-cause mortality.